GRI Bio, Vallon Pharmaceuticals to merge for advancing NKT cell regulators

GRI Bio, a privately held clinical stage biotech company, will merge with a wholly-owned subsidiary of Nasdaq-listed Vallon Pharmaceuticals in an all-stock transaction. The combined ... Read More